Oxford Immunotec Global PLC Ordinary Shares
OXFD
OXFD was delisted on the 5th of March, 2021.
74 hedge funds and large institutions have $296M invested in Oxford Immunotec Global PLC Ordinary Shares in 2018 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 32 increasing their positions, 27 reducing their positions, and 11 closing their positions.
19% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 27
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 77 → 74 (-3)
12% less capital invested
Capital invested by funds: $337M → $296M (-$41.2M)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$14.8M |
| 2 |
BC
Broadfin Capital
New York
|
+$4.56M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$3.21M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$2.22M |
| 5 |
DM
Deerfield Management
New York
|
+$2.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12M |
| 2 |
PA
Perceptive Advisors
New York
|
-$6.99M |
| 3 |
RI
RTW Investments
New York
|
-$5.25M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$4.93M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.73M |
OXFD Hedge Fund Activity: Q1 2018 in Review
74 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Oxford Immunotec Global PLC Ordinary Shares (OXFD) for Q1 2018, worth a combined $296M — down 12% from $337M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of OXFD and 8 opened new positions — a net loss of 3 holders — while 27 trimmed existing stakes and 32 added.
The largest buyer was Consonance Capital Management, adding an estimated $14.8M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $12M sold.
- 74 institutional investors held Oxford Immunotec Global PLC Ordinary Shares (OXFD) as of Q1 2018, down from 77 in Q4 2017.
- Funds reported $296M of Oxford Immunotec Global PLC Ordinary Shares stock for Q1 2018, down 12% quarter-over-quarter.
- 8 funds opened new Oxford Immunotec Global PLC Ordinary Shares positions in Q1 2018 and 11 closed out, a net change of -3 holders.
- The largest Oxford Immunotec Global PLC Ordinary Shares buyer in Q1 2018 was Consonance Capital Management, an estimated $14.8M added.
- The largest Oxford Immunotec Global PLC Ordinary Shares seller in Q1 2018 was T. Rowe Price Associates, an estimated $12M sold.
Based on aggregated 13F filings for Q1 2018.